What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com . Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM) , OPKO Health (OPK) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Activision Blizzard (ATVI) , Ford Motor (F) , Gilead Sciences (GILD) , CymaBay Therapeutics (CBAY) , Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD) .

NASDAQ:CGIX

Cancer Genetics (CGIX) Stock Price, News & Analysis

→ Nerd Investor Reveals Secret To Make Money With A.I. (From InvestorPlace) (Ad)

Free CGIX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.18
▼
$0.20
50-Day Range: $0.15
▼
$4.61
52-Week Range: $2.11
▼
$17.50

Volume: 19,116 shs
Average Volume: 2.44 million shs
Market Capitalization: $792,490.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Social Media

Get Cancer Genetics alerts:

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Cancer Genetics Stock (NASDAQ:CGIX)

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

CGIX Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Health Care and Social Assistance
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:CGIX
CUSIP: N/A
CIK: N/A
Web: www.cancergenetics.com
Phone: (201) 479-1357
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $6.33 million
Price / Sales: 0.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,085,000
Free Float: N/A
Market Cap: $792,490.00
Optionable: Not Optionable
Beta: 2.72

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Andrew D. C. LaFrence
President, Chief Executive & Financial Officer

Key Competitors

View All Competitors

CGIX Stock Analysis - Frequently Asked Questions

What is Panna Sharma's approval rating as Cancer Genetics' CEO?: 28 employees have rated Cancer Genetics Chief Executive Officer Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among the company's employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Cancer Genetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Activision Blizzard (ATVI), Ford Motor (F), Gilead Sciences (GILD), CymaBay Therapeutics (CBAY), Synergy Pharmaceuticals (SGYP) and TherapeuticsMD (TXMD).

This page (NASDAQ:CGIX) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cancer Genetics (CGIX) Stock Price, News & Analysis

About Cancer Genetics Stock (NASDAQ:CGIX)

CGIX Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CGIX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info